Latest News

Italian engineering group Maire is embroiled in an escalating cross-border legal battle with EuroChem over a halted Russian fertiliser complex, with conflicting Russian and Western court rulings and recent Bombay High Court restrictions creating material uncertainty for its contracts and financing outside Russia. The push by Maire to secure interim relief from the High Court of England and Wales underscores how enforcement of Russian judgments abroad has become a potential threat to the...

In January 2026, SEALSQ Corp reported preliminary unaudited 2025 revenue of US$18,000,000, reiterated very large 2026 revenue growth guidance, and unveiled multiple quantum-security initiatives including an India-focused semiconductor joint venture and potential multi-stage investment in French quantum firm Quobly. Together with live post-quantum robotics tests and participation in high-profile policy and investor forums, these moves position SEALSQ as an increasingly influential player at...

What FIGS’ Recent Performance Tells You FIGS (FIGS) has been catching investor attention after a sharp total return over the past year, paired with annual revenue of about US$581.0m and net income of roughly US$17.6m. See our latest analysis for FIGS. At a share price of US$11.60, FIGS has seen a sharp 47.6% 90 day share price return and a 95.3% 1 year total shareholder return, suggesting momentum has picked up even after a recent 5.9% 1 day pullback. If FIGS has piqued your interest, it...

Recent share performance snapshot Without a specific news catalyst driving trading today, United Therapeutics (UTHR) still gives you a fair bit to work with based on recent price moves and the latest fundamental snapshot. The stock closed at US$464.93, with a 1 day return of about a 1.5% decline and a 7 day move of roughly a 3.8% decline. Over the past month the share price shows about a 9% decline, while the past 3 months reflect roughly a 7.3% gain. On the fundamentals side, United...

TE Connectivity (TEL) is back in focus after recent analyst commentary and investor letters highlighted its role in automotive and industrial connectivity, along with its exposure to AI related technology, prompting fresh interest in the stock. See our latest analysis for TE Connectivity. TE Connectivity’s recent 7 day share price return of about 4% and 30 day share price return above 8%, alongside a 1 year total shareholder return near 68%, suggests momentum building around its role in...

Why Roche Holding (SWX:ROG) is on investors’ radar today Roche Holding (SWX:ROG) is drawing attention after recent share price moves, with the stock last closing at CHF 348.90 and showing double digit returns over the past month and past 3 months. For investors, that combination of recent performance and the company’s sizeable pharmaceuticals and diagnostics footprint raises the question of how the current price lines up with its fundamentals and value characteristics. See our latest analysis...

Understanding Shell after recent performance Shell (LSE:SHEL) has drawn fresh attention after recent share price moves, with the stock recording a 0.2% gain over the past day and positive returns over the past week and month. See our latest analysis for Shell. Looking beyond the latest move, Shell’s 7 day share price return of 4.26% and 30 day return of 3.57% sit alongside a year to date share price return close to flat. The 5 year total shareholder return of 135.89% highlights how reinvested...

Why 10x Genomics is back on investors’ radar 10x Genomics (TXG) has attracted fresh attention after pairing a mixed 2025 revenue update with new collaborations in autoimmune disease, oncology, immuno-oncology and transplant research across several major medical institutions. See our latest analysis for 10x Genomics. The cluster of new collaborations around autoimmune disease, oncology, immuno-oncology and transplant research has arrived alongside a 30-day share price return of 30.29% and a...

Earlier this week, Eve Holding, through its subsidiary EVE UAM, LLC, entered into a syndicated credit agreement that provided a US$150,000,000 advance from a group of international banks to fund supplier payments and core production and sales activities, with repayments scheduled over four and five years at Term SOFR plus 3.10% interest. A key detail is that Eve Holding has guaranteed EVE UAM’s obligations under this facility, signaling a strong parent-level commitment to supporting the...

Why TOTO Stock Is On Investors’ Radar Today TOTO (TSE:5332) has drawn attention after recent share price moves, with the stock showing double digit returns over the past month and over the past 3 months. This has prompted investors to reassess its current valuation and fundamentals. See our latest analysis for TOTO. At a share price of ¥4,724, TOTO has seen a 6.56% 7 day share price return and a 12.10% 30 day share price return, while its 1 year total shareholder return of 30.65% points to...

Resolute Mining has already hosted a webcast and conference call in which CEO Chris Eger presented the company’s Q4 2025 Quarterly Activities Report and outlined operational guidance for 2026. This detailed briefing underlines management’s emphasis on transparency and may give investors clearer visibility into project timelines, cost discipline, and growth priorities. We’ll now examine how the Q4 results and newly outlined 2026 guidance could influence Resolute Mining’s existing investment...

Why Ensign Group is on investors’ radar today Ensign Group (ENSG) is drawing attention after recent share price moves, with the stock last closing at $180.57. Investors are weighing that price against the company’s earnings profile and recent return history. See our latest analysis for Ensign Group. The recent 1 day share price decline of 1.62% to $180.57 comes after a 7 day share price return of 3.85%, while the 1 year total shareholder return of 32.22% suggests momentum has been building...

Sichuan Kelun-Biotech Biopharmaceutical recently announced that its TROP2-directed ADC sacituzumab tirumotecan, combined with MSD’s KEYTRUDA, received Breakthrough Therapy Designation in China for first-line treatment of certain advanced non-small cell lung cancer patients, while its CEO highlighted pipeline progress and globalisation plans at the J.P. Morgan Healthcare Conference. The clustering of multiple Breakthrough Therapy Designations around sacituzumab tirumotecan, alongside...

If you are wondering whether Ziff Davis is a bargain or a value trap at its current US$37.48 share price, you are not alone. The stock has returned 3.6% over the last 7 days and 4.8% over the last 30 days. Year to date it is at 10.3%, with a 31.8% decline over 1 year and a 56.1% decline over 3 years. These mixed returns sit against an ongoing stream of corporate updates and portfolio activity that continue to keep Ziff Davis on investors' watchlists. Together, these developments help explain...

If you are wondering whether Super Micro Computer's share price still lines up with its underlying value, this article will walk through what the current numbers actually suggest. The stock recently closed at US$32.64, with returns of 8.2% over 7 days, 11.1% over 30 days, 5.4% year to date, 5.9% over 1 year, and a very large 3 year and 5 year return that is more than 7x the starting point. Recent news coverage has focused on Super Micro Computer's role in high performance computing and AI...

If you are wondering whether Archer Aviation’s current share price lines up with its underlying value, you are not alone. This article is built to help you frame that question clearly. The stock recently closed at US$8.86, with returns of 0.6% over 7 days, 16.9% over 30 days, 9.0% year to date and 0.5% over 1 year, while the 3 year return sits at a very large 215.3% and the 5 year return at a 16.4% decline. Recent attention around Archer Aviation has centered on the broader electric air taxi...

If you are wondering whether Mitsubishi's share price still offers value after a strong run, this article walks through what the current valuation might be telling you. The stock last closed at ¥4,055, with returns of 7.2% over 7 days, 12.6% over 30 days, 11.0% year to date, 70.8% over 1 year, 210.6% over 3 years and a very large gain over 5 years. Recent coverage around Mitsubishi has focused on its role as a major Japanese trading house and its exposure to global commodities and industrial...

If you are wondering whether Aker BP's share price still offers value at current levels, this article will walk through what that price could imply about the stock. Aker BP recently closed at NOK 278.9, with returns of 6.2% over the last 7 days, 13.6% over 30 days, 7.3% year to date, 21.1% over 1 year and 84.9% over 5 years, which may prompt questions about how much expectation is already reflected in the price. Recent coverage around Aker BP has focused on its position in the energy sector...

If you are wondering whether ICON's current share price reflects its true worth, you are not alone. This article will walk through what the numbers are actually saying about value. Over shorter timeframes, ICON's share price has moved only modestly, with a 0.7% return over the last week and 1.8% over the last month, while the year to date return of 3.2% decline and 1 year return of 7.8% decline contrast with a 21.1% decline over 3 years and 15.6% decline over 5 years. These returns sit...

If you are wondering whether RTX is still reasonably priced after a strong run, this article will walk through what the current share price might be implying about future value. RTX recently closed at US$201.92, with returns of 7.1% over 7 days, 14.0% over 30 days, 7.8% year to date, 69.8% over 1 year, 129.0% over 3 years and 235.1% over 5 years. This naturally raises questions about how much optimism is already reflected in the stock. Recent headlines around RTX have focused on the company...

Goodman’s Hong Kong data centre expansion and what it could mean for ASX:GMG Goodman Group (ASX:GMG) is in focus after the Goodman Hong Kong Data Centre Partnership, launched in July 2025, backed its management of six Hong Kong data centres totaling 180 MW of IT capacity. See our latest analysis for Goodman Group. The Hong Kong data centre partnership sits against a mixed share price backdrop, with a 10.22% 1 month share price return and 4.67% 7 day gain offset by a 6.15% 3 month decline and...

Why Takeda Pharmaceutical Stock Is On Investors’ Radar Takeda Pharmaceutical (TSE:4502) has recently drawn attention after a strong run in the past 3 months, with the share price and fundamentals giving investors new data points to assess its longer term appeal. See our latest analysis for Takeda Pharmaceutical. The recent 90 day share price return of 21.05% and 30 day share price return of 12.98% suggest momentum has been building, while a 1 year total shareholder return of 31.35% reflects a...

Why Aurizon’s latest buy-back and lapsed performance rights matter Aurizon Holdings (ASX:AZJ) has cancelled more than 36 million ordinary shares through an on-market buy-back, while a separate 212,819 performance rights have lapsed unvested, together trimming both current and potential future equity on issue. See our latest analysis for Aurizon Holdings. The buy-back and lapsed performance rights come after a steady 90-day share price return of 7.76% and a 1-year total shareholder return of...

Citizens Financial Group previously announced that it would release its fourth quarter and full-year 2026 results on January 15, 2027, with a press release at approximately 6:20 a.m. Eastern and a conference call at 9:00 a.m., both accessible via its investor relations website. Beyond the timing update, Citizens has outlined an ambitious plan centered on substantial projected earnings growth, expanding private banking, expiring legacy interest rate hedges, and efficiency gains from AI, all...